Israel Launches National Trial Using Psychedelics for PTSD
Translated & summarized from Arutz Sheva by baba
Israel's Ministry of Health will initiate its first national trial using MDMA and psilocybin to treat hundreds of PTSD patients. The three-year study aims to provide new options for those unresponsive to current therapies, especially following the surge in trauma cases since October 7th. Treatments will be administered under strict medical supervision in clinics, with no take-home prescriptions to ensure safety and prevent misuse.
The story in 6 lines · by baba
- Israel's Ministry of Health will conduct its first national trial using MDMA and psilocybin for PTSD.
- The trial will involve hundreds of patients with moderate to severe chronic PTSD.
- It aims to offer new treatment options for those unresponsive to conventional therapies.
- Substances will be administered under strict medical supervision in clinical settings.
- The study is a response to the rise in PTSD cases since October 7th.
- Participants will not receive take-home prescriptions for the substances.
Israel's Ministry of Health is set to lead the country's first national trial aimed at treating hundreds of post-traumatic stress disorder (PTSD) sufferers with consciousness-altering substances. The experiment, scheduled to commence in the coming weeks and last approximately three years, will investigate the efficacy of MDMA, the active compound in ecstasy, and psilocybin, found in magic mushrooms, as adjuncts to tightly supervised psychotherapy.
The initiative comes in response to a sharp increase in PTSD diagnoses since October 7th, seeking to offer an alternative treatment for individuals who have not found sufficient relief through conventional therapies. The trial is specifically designed for patients with moderate to severe chronic PTSD who have exhausted standard first-line treatments. Prospective participants will undergo thorough psychiatric and physical evaluations to ensure suitability.
A senior Ministry of Health official explained that the war's impact and the subsequent rise in trauma cases necessitated exploring new therapeutic avenues. While existing trauma-focused treatments exist, they do not guarantee full recovery for all patients, some of whom struggle to adhere to therapy due to the intensity of their traumatic memories and experiences. "Due to the widespread morbidity, we thought it would be right to elevate research into psychoactive substances to the national level, to gain a better perspective on efficacy and also to provide another way out for patients who are currently in a bad place with their treatment," the official stated.
The trial protocol involves three stages: preparatory sessions to build therapeutic rapport and coping strategies, the administration of the psychoactive substance over two to three sessions lasting six to eight hours each in a licensed clinic under strict medical supervision, and follow-up sessions to process experiences and integrate insights into daily life. Crucially, the substances will only be administered in a clinical setting, with no take-home prescriptions, to prevent unsupervised use and avoid issues seen with medical cannabis distribution. The ministry emphasizes that MDMA and psilocybin are not intended for daily stress relief and, within a controlled clinical setting, do not cause physical dependence.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 1Right 1
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
